{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-039986","form_type":"8-K","ticker":"XTNT","cik":"0001453593","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.121206+00:00","generated_at":"2026-06-08T06:26:44.568207+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Xtant Medical reports record Q3 revenue of $25M, raises FY2023 guidance to $88M-$91M","bullets":["Revenue $25.0M, +73% YoY; organic growth 18%; acquisition contributions 55%.","Net income $9.2M ($0.07 EPS) vs net loss $2.4M ($0.03 loss) in Q3 2022.","Non-GAAP adjusted EBITDA $0.5M, improved from -$0.9M in prior-year period.","Gross margin expanded to 61.3% from 54.6% on production efficiencies and product mix.","FY2023 revenue guidance raised to $88M-$91M from prior $75M-$77M."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-039986","json":"https://secwatch.observer/filing/0001493152-23-039986.json","markdown":"https://secwatch.observer/filing/0001493152-23-039986.md","text":"https://secwatch.observer/filing/0001493152-23-039986.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223039986/0001493152-23-039986-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223039986/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:26:44.568207+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7716a9c8cc4ff275d3909450a5f82ae26ab91d02","claim":"Xtant Medical Holdings, Inc. reported third quarter ended September 30, 2023 results: revenue $25.0 million, net income $9.2 million, or $0.07 per share, EPS $0.07 per share. Guidance raised.","evidence_excerpt":"Xtant Medical Announces Record Third Quarter Revenue of $25 Million Raises 2023 Annual Revenue Guidance to $88 Million - $91 Million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223039986/0001493152-23-039986-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$25.0 million"},{"label":"Net income","value":"$9.2 million, or $0.07 per share"},{"label":"EPS","value":"$0.07 per share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"b03bacb7aed52c137233dc0b5f2adf71a192bb80","claim":"Xtant Medical Holdings, Inc. updated its full year 2023 guidance (raised).","evidence_excerpt":"Xtant Medical raises its expectation for full year 2023 revenue to $88 million to $91 million, up from the Company’s prior guidance of $75 million to $77 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223039986/0001493152-23-039986-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}